Coya Therapeutics appoints Mark Pavao to audit committee
Coya Therapeutics, Inc. submitted an amendment to its March 29, 2026 current report that had announced the appointment of Mark H. Pavao to its Board of Directors, effective April 1, 2026.
Rhea-AI Filing Summary
Coya Therapeutics, Inc. submitted an amendment to its March 29, 2026 current report that had announced the appointment of Mark H. Pavao to its Board of Directors, effective April 1, 2026. At that time, the Board had not yet determined any committee assignments for him.
The company now states that on August 6, 2026 its Board, acting on a recommendation from the Nominating and Corporate Governance Committee, appointed Mr. Pavao to the Audit Committee, effective immediately. Following this decision, the Audit Committee members are Dr. Dov Goldstein (Chair), Dr. Ann Lee, Dieter Weinand and Mark H. Pavao.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Original report date: March 29, 2026
Board appointment effective date: April 1, 2026
Audit Committee appointment date: August 6, 2026
+1 more
4 metrics
Original report date
March 29, 2026
Date of the current report that first disclosed Mark H. Pavao’s board appointment
Board appointment effective date
April 1, 2026
Effective date of Mark H. Pavao joining the Board of Directors
Audit Committee appointment date
August 6, 2026
Date the Board appointed Mark H. Pavao to the Audit Committee
Audit Committee members
4 members
Dr. Dov Goldstein, Dr. Ann Lee, Dieter Weinand and Mark H. Pavao
Key Terms
Audit Committee, Nominating and Corporate Governance Committee, Emerging growth company
3 terms
Audit Committee financial
"appointed Mr. Pavao to the Audit Committee of the Board, effective immediately"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Nominating and Corporate Governance Committee regulatory
"the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Mr. Pavao"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board committee change did Coya Therapeutics (COYA) disclose?
Coya Therapeutics reported that on August 6, 2026 its Board appointed director Mark H. Pavao to the Board’s Audit Committee, effective immediately, following a recommendation from the Nominating and Corporate Governance Committee.
When did Mark H. Pavao join the Coya Therapeutics (COYA) Board of Directors?
Coya Therapeutics previously disclosed that Mark H. Pavao was appointed to its Board of Directors effective April 1, 2026, in a current report dated March 29, 2026, before any committee assignments had been determined for him.
Who are the members of Coya Therapeutics (COYA) Audit Committee after this amendment?
After the August 6, 2026 decision, the Audit Committee consists of Dr. Dov Goldstein (Chair), Dr. Ann Lee, Dieter Weinand and Mark H. Pavao, with Mr. Pavao’s committee appointment effective immediately.
Which committee recommended Mark H. Pavao’s Audit Committee role at Coya Therapeutics (COYA)?
Coya Therapeutics states that its Nominating and Corporate Governance Committee recommended appointing Mark H. Pavao to the Board’s Audit Committee, and the full Board approved this recommendation on August 6, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
